Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms SMET 12, SMET-12, SMET12 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR positive Neoplasms | Phase 2 | CN | 16 Jun 2023 |